Abstract | INTRODUCTION:
Chromophobe renal cell carcinoma is universally accepted as a distinct subtype of renal cell carcinoma. There are conflicting reports on prognosis, and few data on response to treatment exist. Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Current strategies are based on results obtained in the context of clear cell-type renal cell carcinoma. Separate trials for rare histologies seem unfeasible and are unlikely to be performed. For these cases, clinical observations are an important part for advancing therapeutic insight. In recent years, novel tyrosine kinase inhibitors have been shown to have significant clinical benefit in advanced renal cell carcinoma. CASE PRESENTATION: CONCLUSIONS:
|
Authors | Vasiliki Michalaki, Constantine Gennatas |
Journal | Journal of medical case reports
(J Med Case Rep)
Vol. 6
Pg. 115
(Apr 23 2012)
ISSN: 1752-1947 [Electronic] England |
PMID | 22524151
(Publication Type: Journal Article)
|